|
|
|
| |
|
|
| |
The latest prostate cancer news from News Medical |
|
|
|
| |  | | |  High-risk localized and locally advanced prostate cancer patients treated with apalutamide - a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) - plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD,... | | | | |  Recently, the research group led by Dr. Dechao Feng, Lecturer at University College London (UCL) and Distinguished Research Fellow at Zhejiang Provincial People's Hospital, published a review entitled "Intratumoral Androgens and Genetic Variants Driving Therapy Resistance in Prostate Cancer". | | | | |  A new machine-learning approach for prostate-specific membrane antigen (PSMA) treatment of metastatic castration-resistant prostate cancer (mCRPC) could estimate radiation dose to tumors and healthy organs before therapy begins. | | | | |  Ceramides-lipid molecules in cells that affect many physiological functions including cell differentiation, migration, and death-and their metabolites have been implicated in the development of cancer and other conditions. | | | | |  Researchers with the James P. Allison Institute™ at The University of Texas MD Anderson Cancer Center have discovered a new gene expression signature within tumors that can help identify patients with metastatic castration-resistant prostate cancer (mCRPC) who are more likely to experience lasting benefits from combined immunotherapy treatment. | |
|
|
|
|
|
|
|
